#UK #Piramal Pharma #Korsch XM-12 #Morpeth Facility #Morpeth

Advancements in Drug Development at Piramal Pharma Solutions

Piramal Pharma Solutions, recognized as a leading Contract Development and Manufacturing Organization (CDMO), has recently made a significant investment to improve its drug formulation capabilities at its Morpeth facility located in the UK. The company's acquisition of the advanced Korsch XM-12 bilayer tablet press marks a strategic enhancement to its operations, aimed at increasing efficiency and precision in tablet production.

Why the Korsch XM-12?

The Korsch XM-12 bilayer tablet press is designed to meet the growing demand for both single-layer and bilayer solid dosage forms. This innovative equipment will empower the Formulation Development Team at the Morpeth site to produce tablets with exceptional quality and consistency. Importantly, the press is equipped with advanced features, such as sanitary fittings for inlet hoppers and a specialized product chute for handling high potency active pharmaceutical ingredients (APIs). Its design allows for quick changeovers between different production formats, which is crucial for meeting diverse client needs efficiently.

Prioritizing Safety and Quality

Piramal Pharma Solutions has meticulously implemented a robust training program to ensure the Korsch XM-12 is operated safely and effectively. Employees, including scientists and operators, will undergo thorough training conducted alongside Korsch factory technicians. This training includes essential operational protocols tailored to specific roles, ensuring that all team members are well-equipped to handle the sophisticated equipment. Frank Bugg, the Managing Director of the Morpeth facility, emphasized the importance of these preparations, stating that the training will cover critical aspects such as machine operation, troubleshooting, and maintenance.

Enhanced Performance in Tablet Production

The addition of the Korsch XM-12 bilayer tablet press is set to revolutionize tablet production at the Morpeth facility. With its ability to maintain consistent output with minimal operator interaction, the press is expected to streamline manufacturing processes, enhance productivity, and ultimately lead to faster delivery of innovative therapeutic solutions to patients. The facility is committed to upholding rigorous industry standards while meeting Piramal's internal quality requirements.

Commitment to Patients and Innovation

Piramal Pharma Solutions’ investment in the Korsch XM-12 is not just about enhancing production but also reflects the company’s dedication to improving patient outcomes globally. By delivering high-quality, innovative therapies to market more swiftly and effectively, Piramal aims to contribute positively to the healthcare landscape, thereby reducing the burden of diseases.

About Piramal Pharma Solutions

As a part of Piramal Pharma Ltd., Piramal Pharma Solutions provides a range of end-to-end development and manufacturing services across the entire drug lifecycle. With a global presence in North America, Europe, and Asia, the company offers comprehensive solutions ranging from drug discovery to manufacturing of APIs and finished dosage forms. The introduction of state-of-the-art technologies, like the Korsch XM-12, reinforces their commitment to being at the forefront of the pharmaceutical manufacturing sector.

In summary, the addition of the Korsch XM-12 bilayer tablet press at Piramal Pharma Solutions will not only enhance their formulation capabilities but also strengthen their position as a leader in the CDMO landscape. With safety, quality, and patient-centric innovation at the core of their operations, Piramal continues to pave the way for advancements in pharmaceutical manufacturing.